BG Medicine, Inc. is a life sciences company, which engages in the provision of developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The company is headquartered in Waltham, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Follow-Up Questions
What is BG Medicine Inc (BGMD)'s P/E Ratio?
The P/E ratio of BG Medicine Inc is 0
Who is the CEO of BG Medicine Inc?
Dr. Paul Sohmer is the President of BG Medicine Inc, joining the firm since 2013.
What is the price performance of BGMD stock?
The current price of BGMD is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BG Medicine Inc?
BG Medicine Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
